Global CD Antigen Cancer Therapy Market

CD Antigen Cancer Therapy Comprehensive Study by Type (Monoclonal Antibodies, Antibody-Drug-Conjugates, Tri-Functional & Bi-Specific T-Cell Engager Antibodies, Other), Application (Hospitals, Homecare, Specialty Clinics, Others), Drugs Type (Rituximab, Ocrelizumab, Ofatumumab, Obinutuzumab, Others), Sales Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), CD Antigens (CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD70, CD137), Administration Route (Intravenous, Subcutaneous, Others) Players and Region - Global Market Outlook to 2027

CD Antigen Cancer Therapy Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
The market for CD antigen cancer therapy is growing because of an increase in cancer cases around the world. Pharmaceutical companies are currently conducting clinical trials to create innovative therapies, which could enhance the CD antigen cancer therapy market position. Furthermore, the approval of newer CD-directed monoclonal antibodies may encourage competitors to create novel treatments, which could have a considerable impact on CD antigen cancer therapy growth. The CD antigens are widely used to targets a variety of cancer therapeutics such as monoclonal antibodies, antibody-drug-conjugates, tri-functional and bi-specific, and among others. These antigens are used to classify white blood cells (WBC) and are especially important for the diagnosis of lymphomas and leukemias.
This growth is primarily driven by Rising Prevalence Of The Cancer, Advancement In The Biotechnological Sector and Unmet Medical Need and Large Patient Base in Emerging Economies.

Globally, a noticeable market trend is evident Emergence of CAR-T Cell Therapy. The Diseases & Therapeutic Areas sector in the North America region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as AryoGen Biopharma (Iran), Biocad (Russia), Merck (United States), Sandoz (Germany), UCB (Belgium), Genmab (Denmark), Roche Glycart AG (Switzerland), Biogen Inc. (United States), Celltrion (South Korea), Hetero Drugs Limited (India), mAbxience (Spain), MedImmune (United States) and Genentech (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Market Drivers
  • Rising Prevalence Of The Cancer
  • Advancement In The Biotechnological Sector
  • Unmet Medical Need and Large Patient Base in Emerging Economies

Market Trend
  • Emergence of CAR-T Cell Therapy

Restraints
  • High Costs of CD Antigen Cancer Drugs

Opportunities
Favorable Reimbursement Schemes for Cancer Therapy and Fast-tracked Research & Development by Pharma Companies
Challenges
Difficulties in Differentiating CD Target on Cancer Cells

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, CD Antigen Cancer Therapy Study Sheds Light on
— The CD Antigen Cancer Therapy Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the CD Antigen Cancer Therapy industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where CD Antigen Cancer Therapy industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Monoclonal Antibodies
  • Antibody-Drug-Conjugates
  • Tri-Functional & Bi-Specific T-Cell Engager Antibodies
  • Other
By Application
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
By Drugs Type
  • Rituximab
  • Ocrelizumab
  • Ofatumumab
  • Obinutuzumab
  • Others

By Sales Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

By CD Antigens
  • CD19
  • CD20
  • CD22
  • CD30
  • CD33
  • CD37
  • CD38
  • CD70
  • CD137

By Administration Route
  • Intravenous
  • Subcutaneous
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence Of The Cancer
      • 3.2.2. Advancement In The Biotechnological Sector
      • 3.2.3. Unmet Medical Need and Large Patient Base in Emerging Economies
    • 3.3. Market Challenges
      • 3.3.1. Difficulties in Differentiating CD Target on Cancer Cells
    • 3.4. Market Trends
      • 3.4.1. Emergence of CAR-T Cell Therapy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
  • 5. Global CD Antigen Cancer Therapy, by Type, Application, Drugs Type, Sales Channel, CD Antigens, Administration Route and Region (value) (2016-2021)
    • 5.1. Introduction
  • 6. CD Antigen Cancer Therapy: Manufacturers/Players Analysis
    • 6.1. Company Profile
      • 6.1.1. AryoGen Biopharma (Iran)
        • 6.1.1.1. Business Overview
        • 6.1.1.2. Products/Services Offerings
        • 6.1.1.3. Financial Analysis
        • 6.1.1.4. SWOT Analysis
      • 6.1.2. Biocad (Russia)
        • 6.1.2.1. Business Overview
        • 6.1.2.2. Products/Services Offerings
        • 6.1.2.3. Financial Analysis
        • 6.1.2.4. SWOT Analysis
      • 6.1.3. Merck (United States)
        • 6.1.3.1. Business Overview
        • 6.1.3.2. Products/Services Offerings
        • 6.1.3.3. Financial Analysis
        • 6.1.3.4. SWOT Analysis
      • 6.1.4. Sandoz (Germany)
        • 6.1.4.1. Business Overview
        • 6.1.4.2. Products/Services Offerings
        • 6.1.4.3. Financial Analysis
        • 6.1.4.4. SWOT Analysis
      • 6.1.5. UCB (Belgium)
        • 6.1.5.1. Business Overview
        • 6.1.5.2. Products/Services Offerings
        • 6.1.5.3. Financial Analysis
        • 6.1.5.4. SWOT Analysis
      • 6.1.6. Genmab (Denmark)
        • 6.1.6.1. Business Overview
        • 6.1.6.2. Products/Services Offerings
        • 6.1.6.3. Financial Analysis
        • 6.1.6.4. SWOT Analysis
      • 6.1.7. Roche Glycart AG (Switzerland)
        • 6.1.7.1. Business Overview
        • 6.1.7.2. Products/Services Offerings
        • 6.1.7.3. Financial Analysis
        • 6.1.7.4. SWOT Analysis
      • 6.1.8. Biogen Inc. (United States)
        • 6.1.8.1. Business Overview
        • 6.1.8.2. Products/Services Offerings
        • 6.1.8.3. Financial Analysis
        • 6.1.8.4. SWOT Analysis
      • 6.1.9. Celltrion (South Korea)
        • 6.1.9.1. Business Overview
        • 6.1.9.2. Products/Services Offerings
        • 6.1.9.3. Financial Analysis
        • 6.1.9.4. SWOT Analysis
      • 6.1.10. Hetero Drugs Limited (India)
        • 6.1.10.1. Business Overview
        • 6.1.10.2. Products/Services Offerings
        • 6.1.10.3. Financial Analysis
        • 6.1.10.4. SWOT Analysis
      • 6.1.11. MAbxience (Spain)
        • 6.1.11.1. Business Overview
        • 6.1.11.2. Products/Services Offerings
        • 6.1.11.3. Financial Analysis
        • 6.1.11.4. SWOT Analysis
      • 6.1.12. MedImmune (United States)
        • 6.1.12.1. Business Overview
        • 6.1.12.2. Products/Services Offerings
        • 6.1.12.3. Financial Analysis
        • 6.1.12.4. SWOT Analysis
      • 6.1.13. Genentech (United States)
        • 6.1.13.1. Business Overview
        • 6.1.13.2. Products/Services Offerings
        • 6.1.13.3. Financial Analysis
        • 6.1.13.4. SWOT Analysis
  • 7. Global CD Antigen Cancer Therapy Sale, by Type, Application, Drugs Type, Sales Channel, CD Antigens, Administration Route and Region (value) (2022-2027)
    • 7.1. Introduction
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Company Basic Information, Sales Area and Its Competitors
  • Table 2. Company Basic Information, Sales Area and Its Competitors
  • Table 3. Company Basic Information, Sales Area and Its Competitors
  • Table 4. Company Basic Information, Sales Area and Its Competitors
  • Table 5. Company Basic Information, Sales Area and Its Competitors
  • Table 6. Company Basic Information, Sales Area and Its Competitors
  • Table 7. Company Basic Information, Sales Area and Its Competitors
  • Table 8. Company Basic Information, Sales Area and Its Competitors
  • Table 9. Company Basic Information, Sales Area and Its Competitors
  • Table 10. Company Basic Information, Sales Area and Its Competitors
  • Table 11. Company Basic Information, Sales Area and Its Competitors
  • Table 12. Company Basic Information, Sales Area and Its Competitors
  • Table 13. Company Basic Information, Sales Area and Its Competitors
  • Table 14. Research Programs/Design for This Report
  • Table 15. Key Data Information from Secondary Sources
  • Table 16. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. AryoGen Biopharma (Iran) Revenue, Net Income and Gross profit
  • Figure 5. AryoGen Biopharma (Iran) Revenue: by Geography 2021
  • Figure 6. Biocad (Russia) Revenue, Net Income and Gross profit
  • Figure 7. Biocad (Russia) Revenue: by Geography 2021
  • Figure 8. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 9. Merck (United States) Revenue: by Geography 2021
  • Figure 10. Sandoz (Germany) Revenue, Net Income and Gross profit
  • Figure 11. Sandoz (Germany) Revenue: by Geography 2021
  • Figure 12. UCB (Belgium) Revenue, Net Income and Gross profit
  • Figure 13. UCB (Belgium) Revenue: by Geography 2021
  • Figure 14. Genmab (Denmark) Revenue, Net Income and Gross profit
  • Figure 15. Genmab (Denmark) Revenue: by Geography 2021
  • Figure 16. Roche Glycart AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. Roche Glycart AG (Switzerland) Revenue: by Geography 2021
  • Figure 18. Biogen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Biogen Inc. (United States) Revenue: by Geography 2021
  • Figure 20. Celltrion (South Korea) Revenue, Net Income and Gross profit
  • Figure 21. Celltrion (South Korea) Revenue: by Geography 2021
  • Figure 22. Hetero Drugs Limited (India) Revenue, Net Income and Gross profit
  • Figure 23. Hetero Drugs Limited (India) Revenue: by Geography 2021
  • Figure 24. MAbxience (Spain) Revenue, Net Income and Gross profit
  • Figure 25. MAbxience (Spain) Revenue: by Geography 2021
  • Figure 26. MedImmune (United States) Revenue, Net Income and Gross profit
  • Figure 27. MedImmune (United States) Revenue: by Geography 2021
  • Figure 28. Genentech (United States) Revenue, Net Income and Gross profit
  • Figure 29. Genentech (United States) Revenue: by Geography 2021
List of companies from research coverage that are profiled in the study
  • AryoGen Biopharma (Iran)
  • Biocad (Russia)
  • Merck (United States)
  • Sandoz (Germany)
  • UCB (Belgium)
  • Genmab (Denmark)
  • Roche Glycart AG (Switzerland)
  • Biogen Inc. (United States)
  • Celltrion (South Korea)
  • Hetero Drugs Limited (India)
  • mAbxience (Spain)
  • MedImmune (United States)
  • Genentech (United States)
Select User Access Type

Key Highlights of Report


Mar 2022 236 Pages 97 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global CD Antigen Cancer Therapy Market Quantitative research analysis
Global CD Antigen Cancer Therapy Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The CD Antigen Cancer Therapy market is expected to see a CAGR of % during projected year 2021 to 2027.
Top performing companies in the Global CD Antigen Cancer Therapy market are AryoGen Biopharma (Iran), Biocad (Russia), Merck (United States), Sandoz (Germany), UCB (Belgium), Genmab (Denmark), Roche Glycart AG (Switzerland), Biogen Inc. (United States), Celltrion (South Korea), Hetero Drugs Limited (India), mAbxience (Spain), MedImmune (United States) and Genentech (United States), to name a few.
North America is dominating the CD Antigen Cancer Therapy Market.

Know More About Global CD Antigen Cancer Therapy Market Report?

Have a Query? Click Here

Other Related Reports

Neuroprotection Comprehensive Study by Type (Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic...
$ 3750
Human Rabies Immunoglobulin Comprehensive Study by Side effects (Pain, Fever, Headache, Others), Rabies (Encephalitic, Paralytic), Immunoglobulin (IgG, IgM, IgA, IgD, IgE) Players and Region - Globa...
$ 3500
Flu Vaccine Comprehensive Study by Type (Whole Virus Vaccines, Split Virus Vaccines, Subunit Vaccines, Live Attenuated Virus Vaccines), Application (For Children (6 months to 3 years), For Adults and...
$ 3450
Vascular Graft Comprehensive Study by Raw Material (Polyester, EPTFE, Polyurethane, Biosyntheti), Indication (EVAR (Abdominal Aneurysm Repair & Thoracic Aneurysm0, Peripheral Vascular Repair, Hemodia...
$ 3450
Hirudin Comprehensive Study by Type (Natural Hirudin, Recombinant Hirudin), Disease Indication (Heparin-Induced Thrombocytopenia, Unstable Angina, Tumors, Others) Players and Region - Global Market O...
$ 3500
Prednisolone Acetate Comprehensive Study by Type (Prednisolone Acetate Tablet, Prednisolone Acetate Liquid, Prednisolone Acetate Emulsifiable Paste), Application (Hypersensitivity Disease, Autoimmune...
$ 3450